Michael Pfreundschuh

发表

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

Dirk Hasenclever, Markus Loeffler, Christian Rübe, 2004, Blood.

New drugs for aggressive B-cell and T-cell lymphomas.

M. Pfreundschuh, Michael Pfreundschuh, N. Murawski, 2010, The Lancet. Oncology.

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.

Carsten Müller, M. Pfreundschuh, M. Wiesen, 2012, Blood.

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.

Martin Dreyling, Michael Unterhalt, Wolfgang Hiddemann, 2006, Blood.

Rituximab in high-grade lymphoma.

M. Pfreundschuh, Michael Pfreundschuh, N. Murawski, 2010, Seminars in hematology.

German High-Grade Non-Hodgkin Lymphoma Study Group analysis of patients with T-cell lymphoma treated in studies of the Treatment and prognosis of mature T-cell and NK-cell lymphoma: an

Markus Loeffler, Anthony D. Ho, Norbert Schmitz, 2013 .

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

Markus Loeffler, Anthony Ho, Norbert Schmitz, 2008, The Lancet. Oncology.

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

Dirk Hasenclever, Markus Loeffler, Norbert Schmitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Stefano Monti, Gad Getz, Ignaty Leshchiner, 2018, Nature Medicine.

Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic Melanoma1

Danila Valmori, Hans-Georg Rammensee, Pedro Romero, 2002, The Journal of Immunology.

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

Dirk Hasenclever, Markus Loeffler, Christian Rübe, 2004, Blood.

Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults.

Dirk Hasenclever, Rainer Spang, Michael Hummel, 2011, Blood.

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.

Michael Hummel, Markus Loeffler, Peter Möller, 2010, Blood.

Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.

Michael Hallek, Ulrich Keller, Mathias Witzens-Harig, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SSX: A multigene family with several members transcribed in normal testis and human cancer

Özlem Türeci, Ugur Sahin, M. Pfreundschuh, 1997, International journal of cancer.

Diffuse large B-cell lymphoma.

Stefano A Pileri, Claudio Agostinelli, S. Pileri, 2013, Critical reviews in oncology/hematology.

Serological identification of breast cancer‐related antigens from a Saccharomyces cerevisiae surface display library

M. Pfreundschuh, L. Old, F. Neumann, 2005, International journal of cancer.

Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients.

Gerd Ritter, Dirk Jäger, D. Jäger, 2003, Cancer immunity.

RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.

Verena I Gaidzik, Lars Bullinger, Brigitte Schlegelberger, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.